Results 181 to 190 of about 277,876 (250)

Increased choroidal stromal area in patients with active Graves' ophthalmopathy based on binarisation method of optical coherence tomographic images. [PDF]

BMJ Open Ophthalmol
Zhou M, Wu D, Cai L, Wang C, Su Y, Li Y, Ke W, Chen T, Hong S, Xiao H, Wan P.   +10 more
europepmc   +1 more source

Transnasal endoscopic orbital inner wall decompression combined with penetrating keratoplasty for corneal ulcer perforation in Graves' ophthalmopathy: A case report. [PDF]

Medicine (Baltimore)
Wang P, Han Z, Li X, Lin R, Yuan H.
europepmc   +1 more source

Assessment of Schlemm's canal with swept-source optical coherence tomography in Graves' ophthalmopathy. [PDF]

Graefes Arch Clin Exp Ophthalmol
Gün RD, Yazıcıoğlu T, Oklar M, Gökkaya N.   +3 more
europepmc   +1 more source

Synergistic Therapy for Graves' Ophthalmopathy-Associated Eyelid Retraction: Steroid, 5-FU, and Botulinum Neurotoxin a Combination. [PDF]

J Clin Med
Kim Y, Lew H.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy

Thyroid, 2021
Background: We report the therapeutic use of K1-70™, a thyrotropin receptor (TSHR) antagonist monoclonal antibody, in a patient with follicular thyroid cancer (FTC), Graves' disease (GD), and Graves' ophthalmopathy (GO).
Mabel Ryder, M. Wentworth, A. Algeciras-Schimnich, J. Morris, J. Garrity, J. Sanders, Stuart Young, P. Sanders, J. Furmaniak, B. Rees Smith   +9 more
semanticscholar   +1 more source